ArticleCureus2025
Rapidly Progressive Joint Destruction in Idiopathic Multicentric Castleman's Disease: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castleman's disease (CD) is a group of lymphoproliferative disorders characterized by common morphological features on lymph node biopsy, with idiopathic multicentric Castleman's disease (iMCD) being a notable subtype. Here, we report a 69-year-old Japanese iMCD patient complicated by rapidly progressive joint destruction. Her joint destruction progressed rapidly around the time of her iMCD diagnosis, and she underwent right total hip arthroplasty (THA). Synovial tissue revealed rheumatoid arthritis (RA)-like synovitis. Joint destruction continued to progress even after tocilizumab (TCZ) was initiated for iMCD. Before long, she underwent left THA. Joint destruction due to cytokines other than interleukin-6 (IL-6), or other inflammatory pathologies, was suspected. Mechanistic target of rapamycin (mTOR) activation in iMCD may promote synovitis and joint erosion by regulating immune cell function and osteoclast differentiation. Although there are common pathological mechanisms between iMCD and destructive synovitis (RA-like synovitis), a case of rapidly progressive bone destruction has not been previously reported. Therefore, we report a unique case of iMCD complicated by destructive synovitis (RA-like synovitis) to contribute to the understanding of these overlapping disease mechanisms and potential therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.